A key emerging characteristic of belzutifan-based therapies is their ability to produce a long-lasting duration of response. This creates a notable "tail of the curve" in survival plots, suggesting belzutifan adds significant durability to combination regimens.
Contrary to the assumption that two drugs are always more toxic than one, the Lenvatinib-Belzutifan combination in the LightSpark-011 trial presented a different, but not quantifiably worse, toxicity profile compared to cabozantinib monotherapy, challenging conventional thinking on combination therapy side effects.
An observed signal for cardiac dysfunction in the Lenvatinib-Belzutifan arm of a recent trial is causing concern among clinicians. The lack of detailed characterization for this toxicity makes it a significant point of discussion and an area requiring more data before the regimen's safety profile is fully understood.
Across multiple recent trials, a consistent finding is that if a bladder cancer patient's circulating tumor DNA (ctDNA) does not clear after treatment, it is an extremely poor prognostic sign. This strong signal suggests that these patients should likely be switched to a different therapeutic approach immediately.
The addition of belzutifan to adjuvant pembrolizumab for kidney cancer exacerbates the existing problem of over-treatment. Since about half of patients are already cured by surgery alone, this combination strategy means "doubly over-treating" a large population with added toxicity for no additional benefit.
Despite some positive clinical trial data for AKT inhibitors in prostate cancer, expert opinion suggests this class of drugs is unlikely to see the light of day in routine clinical practice. Skepticism remains about their overall impact, with a feeling that they do not represent a new, meaningful chapter for treatment.
The transformative efficacy of EV-Pembro has ushered in a new, aggressive treatment philosophy for both muscle-invasive and metastatic bladder cancer. The approach is to administer the combination upfront to gain rapid disease control, and only then make subsequent decisions about surgery, radiation, or further therapy.
Subgroup analysis from the LightSpark-011 trial suggests a clear gradation of benefit for the lenvatinib-belzutifan combination. Favorable-risk patients appeared to benefit the most, while the benefit diminished in intermediate and poor-risk groups, pointing towards a potential patient selection strategy based on IMDC risk.
The demonstrated superiority of the enfortumab vedotin (EV) and pembrolizumab combination over platinum chemotherapy has effectively made the Galski criteria, used for determining cisplatin eligibility, irrelevant. This marks a major paradigm shift in how frontline bladder cancer is approached, moving beyond platinum-based decisions.
Achieving a pathologic complete response (path CR) in the bladder after neoadjuvant therapy is a marker of drug efficacy, not a signal to stop treatment. Because patients die from metastatic, not local, disease, a path CR should be seen as a reason to "double down" on the effective systemic therapy to eradicate micrometastases.
A contrarian viewpoint, dubbed the "Gillison Paradox," argues that patients achieving a complete response are precisely the ones who should receive more therapy. Their strong response indicates drug sensitivity, making it logical to continue treatment to eradicate any remaining micrometastatic disease, rather than de-escalating.
Recent phase 3 trial data highlights a significant gap in care for metastatic castration-resistant prostate cancer (mCRPC). Despite clear guideline recommendations, only about half of patients in the trial received bone-targeted agents, exposing a concerning real-world trend of underutilization of standard-of-care supportive therapy.